Date:12/24/2009

egal proceedings; our ability to complete, integrate and benefit from acquisitions, including the transactions discussed in this news release, dispositions, joint ventures and strategic alliances; changes in government policies, laws and regulations affecting our business, including agricultural and trade policies, tax regulations and biofuels legislation; and other factors affecting our business generally. The forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by federal securities law, we do not have any obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

SOURCE Bunge Limited

'/>"/>

SOURCE Bunge Limited Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Bunge Reports Fourth Quarter Net Income of $245 Million
2. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
3. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
4. Sunrise Biotech Holding Limited Application For Admission to PLUS
5. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
6. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
7. Limited transparency in federal nanotech research may hamper development
8. Application for Listing of Shire Limited Ordinary Shares
9. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
10. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
11. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity